Preventive and unlimited Corrective Repair (Essentialcare or equal) service agreement for a Surface Plasmon Resonance (SPR) Biacore T200 instrument, Base plus two (2) option years
Contract Opportunity Analysis
The Food and Drug Administration, on behalf of the Center for Biologics Evaluation and Research, has issued a Sources Sought Notice to identify capable vendors for a preventive and unlimited corrective repair service agreement for a Cytiva Biacore T200 Surface Plasmon Resonance instrument. The required scope includes one annual scheduled preventive maintenance visit utilizing manufacturer-validated software, unlimited on-site corrective maintenance and emergency repairs with original equipment manufacturer-certified parts, and unlimited access to manufacturer technical support. The period of performance is structured as a base year running from August 30, 2026, through August 29, 2027, followed by two consecutive one-year option periods at the facility in Silver Spring, Maryland. Interested sources must submit a capability statement demonstrating technical expertise, past performance from the last three years, and response capabilities to Suzanne Martella via email at suzanne.martella@fda.hhs.gov by July 17, 2026, at 3:00 PM Central Time.